Plain-English translation of NCT06853535 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether ticagrelor, a blood thinner medication, works better than clopidogrel for people who recently had a mild stroke or TIA (mini-stroke) and whose bodies aren't responding well to clopidogrel. Researchers will measure how well each medication prevents future strokes over 90 days of treatment.
Some patients don't respond well to clopidogrel after a stroke, meaning their blood doesn't thin as much as it should. This trial is testing whether switching to this medication helps prevent another stroke in these patients who show signs of resistance.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either ticagrelor or clopidogrel, both combined with aspirin, for the first 21 days. After that, you'll continue on one medication alone for another 70 days (until day 90 total). You'll have follow-up visits to check how you're doing, monitor for any side effects, and see whether you have another stroke.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
China